JOAN M MILLER
Social Work in Winchester, MA

2011018, Aug 4, 2011

Aug 24, 2010

12/862245

EVANGELOS S. GRAGOUDAS - LEXINGTON MA, US
VASSILIKI POULAKI - ROSLINDALE MA, US
JOAN W. MILLER - WINCHESTER MA, US

A61K 39/395, A61K 31/655, A61K 31/352, A61K 31/409, A61K 31/555, A61P 27/02

4241581, 514150, 514454, 514410, 514184

Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.

2003017, Sep 18, 2003

May 5, 2003

10/429496

Joan Miller - Winchester MA, US
Evangelos Gragoudas - Lexington MA, US
Reem Renno - Boston MA, US

A61K039/395, A61K031/555, A61K038/05, A61K031/409

424/155100, 514/018000, 514/185000, 514/410000

Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.

2006016, Jul 27, 2006

Feb 17, 2004

10/545726

Anthony Adamis - Bronxville NY, US
Joan Miller - Winchester MA, US
Mark Mescher - West Newton MA, US
Evangelos Gragoudas - Lexington MA, US
Jeffrey Borenstein - Holliston MA, US

A61M 31/00

604500000

The invention provides a low-profile, dome-shaped body for attachment to a scleral surface of an eye and defining an internal cavity for receiving a drug or other pharmaceutically active agent. The device has an opening for controllably delivering the drug into the eye at therapeutically effective concentrations over a prolonged period of time. When attached, the device does not affect or otherwise restrict movement of the eye. Features of the invention include an optional drug inlet port and puncture guard, both designed for refilling the device while preventing a needle inserted through the inlet port from contacting the sclera.

2007008, Apr 19, 2007

Jun 2, 2006

11/445956

Joan Miller - Winchester MA, US
Evangelos Gragoudas - Lexington MA, US

A61K 31/555, A61K 31/409, A61K 9/127

424450000, 514185000, 514410000

Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.

2011015, Jun 30, 2011

Aug 24, 2010

12/862234

DAVID ZACKS - ANN ARBOR MI, US
JOAN W. MILLER - WINCHESTER MA, US

A61K 39/395, A61K 38/07, A61K 38/08, A61K 38/18, A61K 31/7088, A61P 27/02

4241581, 514 208, 514 76, 514 44 R

Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.

7803375, Sep 28, 2010

Feb 22, 2006

11/359887

Evangelos S. Gragoudas - Lexington MA, US
Vassiliki Poulaki - Roslindale MA, US
Joan W. Miller - Winchester MA, US

Massachusetts Eye and Ear Infirmary - Boston MA

A61K 39/395, A61K 38/16, A61K 31/66, A61K 33/00, A61K 47/22

4241431, 4241301, 4241381, 4241551, 514 12, 514185, 514410, 540145, 8662

Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.

7811832, Oct 12, 2010

Jul 16, 2004

10/892787

David Zacks - Ann Arbor MI, US
Joan W. Miller - Winchester MA, US

Massachusetts Eye and Ear Infirmary - Boston MA

G01N 33/53, A61K 49/16, A61K 38/00, A61K 39/395, A61K 39/00, C12N 5/00, C12N 5/079, C12N 5/071

436547, 436548, 514 2, 424 92, 4241301, 4241421, 435368, 435366

Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.

2006002, Feb 2, 2006

Jul 27, 2005

11/191162

Joan Miller - Winchester MA, US
Akihisa Matsubara - Nagoya, JP
Deeba Husain - Lexington MA, US
Evangelos Gragoudas - Lexington MA, US

A61F 9/00

128898000, 514913000

The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.

2011014, Jun 16, 2011

Sep 8, 2010

12/877662

JOAN W. MILLER - WINCHESTER MA, US
EVANGELOS S. GRAGOUDAS - LEXINGTON MA, US
REEM Z. RENNO - BOSTON MA, US

A61K 38/00, A61K 31/7052, A61P 27/02

514 208, 514 44 A

Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.

2014002, Jan 23, 2014

Oct 21, 2011

13/882932

Demetrios Vavvas - Boston MA, US
Joan W. Miller - Winchester MA, US
Maki Kayama - Tokyo, JP

A61K 31/4178, A61K 38/00

514 177, 514389

Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.